190 related articles for article (PubMed ID: 11250770)
1. Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations.
Ward DL; Bing-You RG
Endocr Pract; 2001; 7(1):52-8. PubMed ID: 11250770
[TBL] [Abstract][Full Text] [Related]
2. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
3. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
4. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
Serranti D; Indolfi G; Nebbia G; Cananzi M; D'Antiga L; Ricci S; Stagi S; Azzari C; Resti M;
Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
[TBL] [Abstract][Full Text] [Related]
5. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
[TBL] [Abstract][Full Text] [Related]
6. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy.
Marazuela M; García-Buey L; González-Fernández B; García-Monzón C; Arranz A; Borque MJ; Moreno-Otero R
Clin Endocrinol (Oxf); 1996 Jun; 44(6):635-42. PubMed ID: 8759175
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M
Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146
[TBL] [Abstract][Full Text] [Related]
8. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis.
Rotondi M; Minelli R; Magri F; Leporati P; Romagnani P; Baroni MC; Delsignore R; Serio M; Chiovato L
Eur J Endocrinol; 2007 Apr; 156(4):409-14. PubMed ID: 17389454
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature.
Koh LK; Greenspan FS; Yeo PP
Thyroid; 1997 Dec; 7(6):891-6. PubMed ID: 9459633
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
Obołończyk Ł; Siekierska-Hellmann M; Wiśniewski P; Lewczuk A; Berendt-Obołończyk M; Lakomy A; Michalska Z; Radowska D; Moszkowska G; Bianek-Bodzak A; Sworczak K
Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):842-849. PubMed ID: 29039351
[TBL] [Abstract][Full Text] [Related]
11. [Hepatitis C virus infection and thyroid diseases].
Broussolle C; Steineur MP; Bailly F; Zoulim F; Trépo C
Rev Med Interne; 1999 Sep; 20(9):766-73. PubMed ID: 10522298
[TBL] [Abstract][Full Text] [Related]
12. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
[TBL] [Abstract][Full Text] [Related]
13. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.
Mazziotti G; Sorvillo F; Stornaiuolo G; Rotondi M; Morisco F; Ruberto M; Cioffi M; Amato G; Caporaso N; Gaeta GB; Carella C
J Endocrinol Invest; 2002; 25(7):624-30. PubMed ID: 12150338
[TBL] [Abstract][Full Text] [Related]
14. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1).
Hass HG; Klein R; Nehls O; Kaiser S
J Clin Gastroenterol; 2009; 43(5):470-6. PubMed ID: 19247202
[TBL] [Abstract][Full Text] [Related]
15. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective.
Tran HA; Jones TL; Ianna EA; Foy A; Reeves GE
Endocr Pract; 2013; 19(2):292-300. PubMed ID: 23186968
[TBL] [Abstract][Full Text] [Related]
16. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.
Hsieh MC; Yu ML; Chuang WL; Shin SJ; Dai CY; Chen SC; Lin ZY; Hsieh MY; Liu JF; Wang LY; Chang WY
Eur J Endocrinol; 2000 May; 142(5):431-7. PubMed ID: 10802518
[TBL] [Abstract][Full Text] [Related]
17. Thyroid dysfunction in antiviral therapy of chronic hepatitis C.
Dabrowska MM; Panasiuk A; Flisiak R
Hepatogastroenterology; 2010; 57(101):826-31. PubMed ID: 21033237
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.
Gehring S; Kullmer U; Koeppelmann S; Gerner P; Wintermeyer P; Wirth S
World J Gastroenterol; 2006 Sep; 12(36):5787-92. PubMed ID: 17007043
[TBL] [Abstract][Full Text] [Related]
19. The influence of interferon alpha on the induction of autoimmune thyroiditis in patients treated for chronic viral hepatitis type C.
Krupińska J; Wawrzynowicz-Syczewska M; Urbanowicz W; Pobłocki J; Syrenicz A
Endokrynol Pol; 2011; 62(6):517-22. PubMed ID: 22144218
[TBL] [Abstract][Full Text] [Related]
20. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
Bini EJ; Mehandru S
Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
